Breast & Ovarian Cancer Research

Myriad myChoice® is a portfolio of molecular diagnostic tests that give oncologists the information they need to prescribe the right cancer therapy, for the right patient, at the right time.

Let’s find the test that fits your patient best.

Explore Myriad’s Portfolio of Molecular Diagnostic Tests by Cancer Type

Introducing BRACAnalysis CDx®

BRACAnalysis CDx® helps identify patients with breast cancer that are likely to benefit from the PARP inhibitor Lynparza® (olaparib).1,2

Informed Treatment Decisions

Myriad is committed to providing the information patients and their oncologist need to make critical decisions that guide treatment decisions. Precision medicine starts with an understanding of the biology of each patient’s disease, and each test includes actionable biomarkers to guide medical management. Myriad’s myChoice portfolio was created to bring answers you can trust to a key question: how should I treat this disease?

WHO

is Myriad?

Myriad is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties.

WHAT

is Myriad myChoice?

The Myriad myChoice products help oncologists and their patients decide how they should treat their cancer. Myriad myChoice is one component of Myriad’s mission to answer patients’ four most pressing questions in six medical specialties.

WANT

to See the Portfolio?

The Myriad myChoice products help oncologists and their patients decide how they should treat the patient’s cancer. Discover how our tests can help guide cancer therapy decisions in your practice.